A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

May 11, 2026 updated by: Eli Lilly and Company

A Phase 2b, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

400

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  • Phone Number: 317-615-4559
  • Email: LillyTrials@Lilly.com

Study Locations

  • United States
    • Arizona
      • Chandler, Arizona, United States, 85225
        • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
        • Principal Investigator:
          • Yessica Sachdeva
      • Scottsdale, Arizona, United States, 85260
        • Headlands Research - Scottsdale
        • Principal Investigator:
          • Benjamin Clark
      • Tucson, Arizona, United States, 85712
        • The Institute for Liver Health II dba Arizona Liver Health-Tucson
        • Principal Investigator:
          • Anita Kohli
    • California
      • Greenbrae, California, United States, 94904
        • NorCal Medical Research, Inc
        • Principal Investigator:
          • Linda Gaudiani
      • Huntington Park, California, United States, 90255
        • Velocity Clinical Research, Huntington Park
        • Principal Investigator:
          • Stanley Hsia
      • Rolling Hills Estates, California, United States, 90274
        • Peninsula Research Associates
        • Principal Investigator:
          • Lawrence Sher
      • Walnut Creek, California, United States, 94598
        • Diablo Clinical Research, Inc.
        • Principal Investigator:
          • Mark Christiansen
    • Connecticut
      • Stamford, Connecticut, United States, 06905
        • Stamford Therapeutics Consortium
        • Principal Investigator:
          • David Radin
    • Florida
      • Hialeah, Florida, United States, 33012
        • Indago Research & Health Center, Inc
        • Principal Investigator:
          • Jose Cardona
      • Miami, Florida, United States, 33165
        • New Horizon Research Center
        • Principal Investigator:
          • Lazaro Nunez
      • New Port Richey, Florida, United States, 34652
        • Suncoast Clinical Research, Inc.
        • Principal Investigator:
          • Cathy Barnes
      • Orlando, Florida, United States, 32803
        • Charter Research - Winter Park
        • Principal Investigator:
          • Edgardo Rivera-Rivera
      • The Villages, Florida, United States, 32162
        • Charter Research - Lady Lake
        • Principal Investigator:
          • Jeffrey Norton
    • Idaho
      • Ammon, Idaho, United States, 83406
        • Medical Research Partners
        • Principal Investigator:
          • Joseph Moore
    • Illinois
      • Chicago, Illinois, United States, 60640
        • Great Lakes Clinical Trials - Ravenswood
        • Principal Investigator:
          • Rupal Trivedi
    • Kansas
      • Topeka, Kansas, United States, 66606
        • Cotton O'Neil Diabetes & Endocrinology
        • Principal Investigator:
          • susan brian
    • Kentucky
      • Louisville, Kentucky, United States, 40213
        • Monroe Biomedical Research - Louisville
        • Principal Investigator:
          • Harold Bays
    • Massachusetts
      • Needham, Massachusetts, United States, 02492
        • Knownwell
        • Principal Investigator:
          • Angela Fitch
      • New Bedford, Massachusetts, United States, 02740
        • Lucida Clinical Trials
        • Principal Investigator:
          • David Shih
    • Michigan
      • Southfield, Michigan, United States, 48034
        • Headlands Research - Detroit
        • Principal Investigator:
          • Christopher Romero
      • Troy, Michigan, United States, 48098
        • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
        • Principal Investigator:
          • Neil Fraser
    • Missouri
      • City of Saint Peters, Missouri, United States, 63303
        • StudyMetrix Research
        • Principal Investigator:
          • Timothy Smith
      • Springfield, Missouri, United States, 65807
        • Clinvest Headlands Llc
        • Principal Investigator:
          • Ralph Duda
    • Nevada
      • Las Vegas, Nevada, United States, 89128
        • Las Vegas Medical Research
        • Principal Investigator:
          • Cornell Calinescu
    • New York
      • Amherst, New York, United States, 14226
        • Dent Neurologic Institute
        • Principal Investigator:
          • Laszlo Mechtler
      • Rochester, New York, United States, 14609
        • Rochester Clinical Research, LLC
        • Principal Investigator:
          • Patrick Connors
    • North Carolina
      • Greensboro, North Carolina, United States, 27405
        • Medication Management
        • Principal Investigator:
          • James Franklin
      • Monroe, North Carolina, United States, 28112
        • Monroe Biomedical Research
        • Principal Investigator:
          • Awawu Igbinadolor
      • Morehead City, North Carolina, United States, 28557
        • Lucas Research, Inc
        • Principal Investigator:
          • Kathryn Lucas
      • New Bern, North Carolina, United States, 28562
        • Lucas Research, Inc.
        • Principal Investigator:
          • Joseph Maides
    • Ohio
      • Cincinnati, Ohio, United States, 45212
        • CTI Clinical Research Center
        • Principal Investigator:
          • James Maynard
    • South Carolina
      • Greenville, South Carolina, United States, 29607
        • Tribe Clinical Research, LLC
        • Principal Investigator:
          • Ronald Mayfield
    • Tennessee
      • Nashville, Tennessee, United States, 37211
        • Quality Medical Research
        • Principal Investigator:
          • Saras Sharma
    • Texas
      • Austin, Texas, United States, 78745
        • IMA Clinical Research Austin
        • Principal Investigator:
          • Nomita Kim
      • Dallas, Texas, United States, 75251
        • FutureSearch Trials of Dallas
        • Principal Investigator:
          • Michael Downing
      • Houston, Texas, United States, 77079
        • PlanIt Research, PLLC
        • Principal Investigator:
          • Amer Al-Karadsheh
      • San Antonio, Texas, United States, 78240
        • Endeavor Clinical Trials
        • Principal Investigator:
          • Nitendra Agarwal
      • Weslaco, Texas, United States, 78596
        • Texas Valley Clinical Research
        • Principal Investigator:
          • Eduardo Luna
    • Virginia
      • Danville, Virginia, United States, 24541
        • Sovah Clinical Research-River District
        • Principal Investigator:
          • Stephan Jannach
    • Washington
      • Wenatchee, Washington, United States, 98801
        • Central Washington Health Services Association d/b/a Confluence Health
        • Principal Investigator:
          • Kathryn Eren

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • See Master Protocol CWMM (NCT06143956) for inclusion criteria

Exclusion Criteria:

In addition to exclusion criteria in Master Protocol CWMM (NCT06143956):

  • Have type 1 diabetes or type 2 diabetes
  • Have an ongoing history of bradyarrhythmia and/or sinus bradycardia
  • Have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm)
  • Have a history of acute or chronic pancreatitis
  • All concomitant medications should be at a stable dose for at least 3 months prior to screening

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Participants will receive placebo SC
Drug: Placebo
Administered SC
Experimental: Eloralintide Dose 2
Participants will receive eloralintide SC
Drug: Eloralintide
Administered SC
Other Names:
  • LY3841136
Experimental: Eloralintide Dose 3
Participants will receive eloralintide SC
Drug: Eloralintide
Administered SC
Other Names:
  • LY3841136
Experimental: Macupatide Dose 1
Participants will receive macupatide subcutaneously (SC)
Drug: Macupatide
Administered SC
Other Names:
  • LY3532226
Experimental: Eloralintide Dose 1
Participants will receive eloralintide SC
Drug: Eloralintide
Administered SC
Other Names:
  • LY3841136
Experimental: Macupatide Dose 1 + Eloralintide Dose 1
Participants will receive macupatide SC and eloralintide SC
Drug: Eloralintide
Administered SC
Other Names:
  • LY3841136
Drug: Macupatide
Administered SC
Other Names:
  • LY3532226
Experimental: Macupatide Dose 1 + Eloralintide Dose 2
Participants will receive macupatide SC and eloralintide SC
Drug: Eloralintide
Administered SC
Other Names:
  • LY3841136
Drug: Macupatide
Administered SC
Other Names:
  • LY3532226
Experimental: Macupatide Dose 2 + Eloralintide Dose 3
Participants will receive macupatide SC and eloralintide SC
Drug: Eloralintide
Administered SC
Other Names:
  • LY3841136
Drug: Macupatide
Administered SC
Other Names:
  • LY3532226

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Percent Change from Baseline in Body Weight
Time Frame: Baseline, Week 36
Baseline, Week 36

Secondary Outcome Measures

Outcome Measure
Time Frame
Percent Change from Baseline in Body Weight
Time Frame: Baseline, Week 48
Baseline, Week 48
Change from Baseline in Body Mass Index (BMI)
Time Frame: Baseline, Week 36
Baseline, Week 36
Change from Baseline in Body Weight
Time Frame: Baseline, Week 36
Baseline, Week 36
Percentage of Participants who Achieve ≥5% Body Weight Reduction
Time Frame: Week 36
Week 36
Percentage of Participants who Achieve ≥10% Body Weight Reduction
Time Frame: Week 36
Week 36

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Eli Lilly and Company

Investigators

  • Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

February 1, 2028

Study Registration Dates

First Submitted

May 11, 2026

First Submitted That Met QC Criteria

May 11, 2026

First Posted (Actual)

May 15, 2026

Study Record Updates

Last Update Posted (Actual)

May 15, 2026

Last Update Submitted That Met QC Criteria

May 11, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 27844
  • W8M-MC-CWMM (Other Identifier: Eli Lilly and Company)
  • W8M-MC-MC01 (Other Identifier: Eli Lilly and Company)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

IPD Sharing Time Frame

Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

IPD Sharing Access Criteria

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe